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In this paper we present systems for dual modality imaging, combining fluorescence-enhanced diﬀuse optical tomography and
X-ray computed tomography. Fluorescence diﬀuse optical tomography is carried out in a cylindrical geometry, which ensures
optimal sampling and a straight forward integration with the X-ray modality. Specific acquisition protocols and reconstruction
software have been developed to this end. The X-ray computed tomography serves two purposes. First, it provides the anatomical
information in the registered dual modality images. Second, it provides the actual shape and boundaries of the animal as a priori
input to the fluorescence reconstruction algorithm. To evaluate the performance of the optical imaging system, experiments have
been conducted on phantoms, mice with inserted fluorescing capillaries, and finally on mice bearing tumors, ex-vivo and in-vivo.
Experiments on mice with capillaries inserted in diﬀerent region of interest, allow estimating the detection limits of fluorophore
concentrations. The fluorescence reconstructions are shown to be geometrically consistent with the X-ray images. Finally we
demonstrate the capability of the bimodal system to localize real tumours in mice in-vivo. These results show that dual modality
fluorescence-enhanced diﬀuse optical tomography and X-ray computed tomography imaging in cylindrical geometry has a high
potential for small animal tumour evolution studies.
1. Introduction
Three-dimensional near-infrared fluorescence-enhanced
Diﬀuse Optical Tomography (fDOT) has been proven to be
an eﬃcient noninvasive tool for preclinical cancer research
[1, 2]. With it, the biodistribution of fluorescent probes
targeting molecular markers of tumor development can
be quantitatively estimated. Moreover, fDOT can be used
to assess the influence of anti-cancer treatments on the
molecular level, which makes it a relevant technique not
only in fundamental research but also in drug development
[3–5]. fDOT, as a molecular imaging modality analog to PET,
does not readily provide anatomical information. However,
structure can be obtained by combining fDOT with a second
modality providing morphological information, such as
MRI [6, 7], ultrasound [8, 9], or XCT [10–13]. In this way,
obtaining in vivo anatomical and molecular information
simultaneously becomes possible.
In the present work, XCT has been chosen as the second
imaging modality because it provides high resolution, is
relatively cheap, and its integration with optical tomography
in a single instrument is straightforward. The dual-modality-
approach facilitates the interpretation of the measured
data as it allows the coregistration of molecular data with
anatomical information. This way, the animal shape and
boundaries from the XCT can be used as a priori input to
the fDOT reconstruction algorithm.
The data presented in this paper were obtained on two
instruments. The first one is a laboratory setup, which
physically integrates the XCT and the fDOT modality.
The second one is an industrial prototype, based on the
technology tested on the laboratory setup. In contrast to the
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laboratory setup, it features a horizontal rotation axis and the
XCT and fDOT acquisition chains are physically separated.
In both cases, fDOT scanning is performed in a cylindrical
geometry. This approach allows sampling of a larger part
of the animal surface as compared to a planar tomography
setup. This results in superior imaging quality, as was shown
previously [14, 15]. To provide high reconstruction accuracy,
even in very heterogeneous tissue, the fDOT reconstruction
algorithm takes optical heterogeneities into account [16].
In previous work, the laboratory system was character-
ized in terms of linearity, repeatability, detection limit, and
resolution [14]. These studies were based on measurements
taken on phantoms. In the present paper, measurements
are presented that validate the systems and method on
sacrificed mice and on mice in vivo. The fDOT reconstruc-
tions are evaluated in terms of the minimum fluorophore
quantity required to overcome autofluorescence or nonspe-
cific fluorescence, that is, injected fluorescence nontargeted
to tumors, in the localization error of the reconstructed
inclusions, and the presence of artefacts.
In the first part of this paper, we describe the optical
imaging systems with details given about the instrumen-
tation describing the two purposes of the XCT modality.
First, it provides the actual shape and boundaries of the
measured animal as a priori input to the fDOT reconstruc-
tion algorithm. Second, it provides anatomical information
in the dual-modality images registered. The second part is
devoted to the description of the method and algorithm used
for the fDOT reconstruction. The third part presents results
obtained on mice. In a first study, dead mice with a capillary
containing fluorophore inserted in the trachea or in the
abdomen were imaged on the laboratory setup. The results
validate the registration between the XCT and fDOT images.
In particular, the error in localizing the fluorescent inclusion
was found to be smaller than 1mm. This study also allowed
determining the minimum fluorophore quantity necessary
to overcome the signal due to natural or nonspecific
fluorescence. Finally, experiments on mice bearing diﬀerent
types of tumors are presented. Two independent studies are
discussed. The first one was conducted on the laboratory
setup on dead mice bearing lung tumors. The second one
was carried out on the industrial setup in vivo on live mice
bearing subcutaneous tumors in the pelvic area.
2. Bimodal Instrumentation
2.1. Laboratory Setup. The cylindrical geometry is the most
suitable geometry to deal with both modalities since XCT
instruments are common in this geometry. Moreover, it
allows a uniform scan of the entire object’s surface, which
favors the excellent performances of the system in terms of
sensibility and isotropic resolution along all axes [15]. Previ-
ous studies have led to the development of a planar fDOT
continuous wave (CW) tomograph [16–19]. To cope with
this new geometry, we developed a cylindrical laboratory
bench demonstrator as described on Figure 1.
The position of the illumination relative to the detection
system, defining the optical axis, is fixed, mounted on an
θ
X-sensor
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Figure 1: Schematic of the bimodal laboratory setup.
optical table. The optical axis is horizontal (in the x, y plane),
and the observed animal is placed vertically on a rotation
stage with a vertical rotation axis (around z), see Figure 2(a).
Note that this geometry is dual from the one used on classical
XCT systems where the source-detector pair is rotating. In
order to scan vertically (along z) the examined object, the
optical chain is mounted on synchronized translation stages
and controlled by a computer.
The XCT axis defined by the relative position of the
X-ray detector and the X-ray generator has been placed
perpendicular to the optical axis in the x, y plane. The
optical chain bulk has been optimized according to X-
ray constraints: geometric constraints, protection against
radiation, against reflections. A geometrical calibration of the
XCT and fDOT system by the use of a dedicated calibration
object (cylindrical phantomwith inserted reference balls that
are visible both in XCT and fDOT modalities) is performed
prior to acquisition and analysis of data.
The fDOT instrument chain consists of a continuous
wave laser source (diode laser HEML, Frankfort Laser
Compagny 685 nm, 60mW), a high-sensitivity CCD camera
(Andor DV438) and a combination of filters (coloured RG9,
band-pass filter Semrock 775/46, and interference filter ALP
770) for fluorescence detection. The excitation and emission
wavelengths of the system and the fluorophores are chosen
in the visible range, close to NIR, that is, the so-called
therapeutic window to optimize transmission through the
whole animal. A custom-made, easy to use holder presented
in Figures 2(b)–2(d) has been designed for use with both
modalities, that ensures the animal is immobile and in an
almost “natural” position even though it is vertical.
2.2. Industrial Prototype. Based on the fDOT system
described above, an fDOT industrial prototype scanner
(see Figure 3(a)) was developed at SCANCO Medical after
industrial transfer of the technology [20]. This scanner fea-
tures a 360◦ projection, transillumination geometry, just as
the lab-setup described in Section 2.1. However, the rotation
axis is horizontal, which allows a more natural position
of the animal and easier anesthesia setup. The change in
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Figure 2: Photograph of the bimodal laboratory setup (a) and of a mouse in the holder (b, c, and d).
(a) (b)
Figure 3: Illustration of the prototype fDOT scanner (a). A dedicated animal-holder is used to move the animal between diﬀerent scanners
to achieve multimodality imaging (b).
scanning-geometry is achieved bymounting the illumination
system and the detection system on a platform that can
be rotated around the animal. The animal is placed on a
holder that can be translated along the rotation axis of the
platform, which allows for uniform sampling of the animal
surface in two directions. An additional advantage of the
horizontal scanning geometry is its increased compatibility
with other imaging technologies. Because the described
geometry is the preferred one in many existing small
animal imaging systems, moving the animal between systems
and thus registering of images from diﬀerent modalities is
simplified. The scanner features two diode lasers emitting
at 650 nm and 690 nm. A fiber switch allows selection of
the excitation wavelength. Fluorescence emission bands are
selected by means of a filter changer comprising interference
filters optimized for Alexa Fluor 680 and Alexa Fluor 750.
Transmission measurements at the excitation wavelength are
performed with an ND filter (OD 2.25) in the detection path.
The whole illumination and detection system is enclosed by
a lightproof housing that allows measurements to be taken
under typical workplace lighting conditions.
While the first lab setup integrates the microCT and
an fDOT system on a single measurement platform, the
present scanner does not yet. MicroCT measurements are
performed on a separate system (vivaCT, SCANCO Medical
AG, Switzerland). The link between the two modalities is
provided by a dedicated animal holder that can be moved
from one system to the other (Figure 3(b)). This holder
is fixed to an adapter on either of the two scanners in a
precise and repeatable manner. As a result, the position of
the animal inside the fDOT system can be determined by a
microCT scan, provided an appropriate geometrical calibra-
tion has been performed once. The geometrical calibration
is achieved prior to the measurements, in a similar manner
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as it is done for the laboratory system, that is to say by
means of a calibration object, which is visible in both, the
XCT and fDOT modalities. The transformation matrix that
relates the coordinate systems to each other is calculated
automatically from the optical and the microCT images by
software developed by the authors.
3. Method
3.1. Eﬀective Coupling of XCT/fDOT. The eﬀective coupling
of XCT/fDOT modalities occurs at diﬀerent levels of the
process. First, the XCT image is used as a priori information
for the fDOT algorithm (external shape of the mouse);
second, it gives anatomical information to help with fDOT
image interpretation.
The X-ray acquisition protocol defines the number of
acquired projections and the voltage, current, and filtering
of the X-ray generator. The reconstruction of the volume of
interest is then conducted using, for example, the classical
Feldkamp algorithm [21].
The optical acquisition protocol defines the reference,
diﬀusion, and fluorescence data acquired according to a set of
angular positions and Z-positions. A dark noise and optical
vignetting eﬀects correction is performed as preprocessing
of the data before they are used in the fDOT algorithm for
reconstruction.
(i) Reference data are acquired on a reference object
(with known optical coeﬃcients) at the excitation
wavelength, for each source-camera position to cal-
ibrate the system for quantification purpose [22].
This calibration is done once, prior to each series of
experiments.
(ii) Diﬀusion and fluorescence data are acquired on
the object to be reconstructed at both excitation
and emission wavelengths, for each source-camera
position.
The method used in the system is described in six Steps
in Figure 4 using the example of a phantom mimicking
the mouse shape and with similar optical properties (μa =
0.24 cm−1, μ′s = 10 cm−1). A solid fluorescent inclusion
(1mm3) visible in XCTmodality has been inserted in it. After
positioning the object or the animal on the bench (Step 1)
and acquisition and reconstruction of XCT data according
to the X-ray acquisition protocol (Step 2), the external shape
of the object is extracted from the XCT volume (Step 3). The
XCT reconstructed volume is then discretized to form amesh
(finite volumes) and used by the fDOT algorithm to solve the
light propagation equation taking into account actual object
boundaries. Figure 5 shows the surface extracted from the
XCT volume (color) superimposed on the XCT image (grey
level) for a mouse imaged on the lab setup.
The laser source is approximated thanks to the diﬀusion
approximation by an isotropic point source—called excita-
tion point source—located inside the object at 1/μ′s from
the boundary. For each of the “detector-source” positions
defined in the optical acquisition protocol, the intersection
of the excitation light beam with the object’s surface is
determined. The intersection point is calculated with a ray-
driven method ((a) in Figure 6). This method calculates
the intersection point of the light ray from the excitation
source with the object’s surface. In the case of an object
with a complex shape, several intersection points may be
found for a single light ray. Hence, the algorithm has to
be capable of selecting the relevant intersection point. The
nearest point to the laser source is selected (entering point)
((b) in Figure 6). The same approach is used to calculate
the projections of the detectors onto the object’s surface.
We finally obtain the geometry used in fDOT reconstruction
described in (c) in Figure 6, with the mesh displayed as black
dots. The excitation point sources obtained with the ray-
driven method described above are represented as red dots
and the detector positions are shown in blue.
The laser scanning and image acquisition is performed
according to the optical acquisition protocol as illustrated on
Figure 4 Step 4. The 3D reconstruction of the fluorescence
yield is then achieved (Step 5) by using the method devel-
oped in our laboratory [23] and described in the next section.
Finally, visualization and quantification of the fluorescence
is performed on a merged volume of both modality images
(Step 6).
3.2. Reconstruction Method. This method allows the recon-
struction of fluorescence even in highly attenuating media
such as the liver or lungs. A map of optical heterogeneities
is reconstructed first from diﬀusion data. It compounds the
intrinsic tissue heterogeneity and the border eﬀects due to
the complex shape of the turbid medium. Then fluorescence
is reconstructed from fluorescence data. In this study, the
propagation of light modeled as a scalar field φ(r) in highly
diﬀusive media (with r position in the studied medium
belonging to a domain Ω with boundary dΩ) is assumed to
follow the diﬀusion approximation equation:
−∇D(r)∇Φ(r) + μa(r)Φ(r) = q0(r) (inΩ), (1)
where q0(r) is the source term and D(r) = [3μa(r)(μa(r) +
μ′s(r))]
−1 is the diﬀusion coeﬃcient, μa(r) is the absorption
coeﬃcient and μ′s(r) is the reduced diﬀusion coeﬃcient.
A simplification of (1) leads to the simplified Helmotz
equation as explained in [24]
−∇2ψ + ηψ = q0δ(r− rs)√
D(rs)
withη = ∇
2
√
D(r)
√
D(r)
+
μa(r)
D(r)
, ψ = √Dφ,
(2)
δ is the Dirac function to modelize a source positioned at
1/μ′s(r) inside the medium. η(r) is a scalar map we call the
“heterogeneities map,” which compounds the attenuation
and reduced scattering coeﬃcients, and can also take into
account eﬀects of diﬀusion variations. TheHelmotz equation
(2) has a solution given by the Green function G and leads
to(3)
ψ = q0√
D(rs)
G(rs, r). (3)
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Z5 = −0.98 cm Z6 = −0.77 cm Z7 = −0.56 cm Z8 = −0.35 cm
Z9 = −0.14 cm Z10 = 0.06 cm Z11 = 0.27 cm Z12 = 0.48 cm
Z13 = 0.69 cm Z14 = 0.9 cm Z15 = 1.11 cm
×10−4
Figure 4: Illustration of the systemmethod in six Steps, ROI (region of interest) selection, XCT reconstruction, surface extraction, and mesh
generation, fDOT image acquisition, fDOT reconstruction, coregistration vizualisation, and quantification of fDOT and XCT images.
y x
z
(a)
yx
z
(b)
Figure 5: XCT reconstructed volume (grey level) and surface extracted from XCT volume used in fDOT reconstruction superimposed
(color).
So, given an η map, we can compute the propagation
functionG(r1, r2) of light in themedium between any points
r1 and r2:
(∇2 − η)G(r1, r2) = −δ(r1 − r2). (4)
By modelling the laser source s as a Dirac delta function
position at rs, (1) and (4) give the excitation density wave
Φx(r) at any point r of the medium:
Φx(rs, r) = λG(rs, r). (5)
λ is a conversion factor related to the laser source
intensity and the detection eﬃciency of the camera and is
determined by calibration on the reference acquisition data.
It is such also dependant on the diﬀusion of the reference
phantom D0
A discrete version of (4) is solved on the mesh extracted
from the X-CT volume. Using its external shape, we complete
the equation system with the “Robin conditions” [25], see
(6), where Φbnd(r) stands for the field at the boundary and
n(r) for the outward normal vector:
Φbnd(r) + αD∇Φbnd · n(r) = 0. (6)
The global reconstruction process is then performed
in two main Steps. We first compute the heterogeneities
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Figure 6: Using the external shape derived from the XCT volume to define the excitation source points. (a) Illustration of the ray-driven
approach. (b) Selection of the relevant excitation source intersection point for complex shapes. (c)Mesh obtained for amouse, used for fDOT
reconstruction. The nodes of the mesh are displayed as black dots. Sources (red dots) are located at 24 azimuth angles and 12 longitudinal
positions. The intensity of fluorescence and excitation light is sampled at the detector positions shown in blue.
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Figure 7: Mouse no. 1: mouse with capillary tube with 5 pmol of Alexa 750 inserted in the lungs area; coregistration of the fDOT and XCT
images (visualization threshold 50%).
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Figure 8: Mouse no. 2: mouse with 2 pmol Alexa 750 inside a capillary tube—visible also in XCT modality on (a) (arrow)—inserted in the
lungs. Coregistration of the fDOT and XCT images (visualization threshold 50%).
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Figure 9: Mouse no. 3, experiment on abdominal area. (a, b) XCT reconstruction only, the heterogeneous aspect of the abdomen is clearly
visible. (c, d) coregistration of the fDOT and XCT images for the mouse, with 5 pmol Alexa 750 inside a capillary tube inserted in the
abdominal area. It is impossible to distinguish specific fluorescence from autofluorescence.
η(r) map by comparison of the Green’s functions (light
propagating between the source s and the detector d)
G(rs, rd) to the excitation measurements. This first Step
(“Heterogeneities” method) is itself an iterative process ini-
tialized with a homogeneous map η0(r). The second Step is
the reconstruction of the fluorescence yield from fluorescent
measurements using the heterogeneity map obtained with
the diﬀusion data, as explained in [22].
As said before, Φx(r) denoted the excited light absorbed
by the fluorophore at point r, so the emitted light equals
to S f (r) = Φx(r)X(r) with X(r) proportional to the
fluorophore concentration in r. The detected signal in
detector d is given in rd. by
Φm(rd) = q0
∫
G(rs, r)√
D(rs)
X(r)
D(r)
G(r, rd)√
D(rd)
dr. (7)
Note that we assume that the medium optical properties
remain constant at the excitation and emission wavelength.
Thus we reconstruct the quantity X(r)/D(r), that is, the
fluorescence concentration divided by the local diﬀusion
coeﬃcient D(r). As demonstrated in [24], unless D(r) is
known, there is no unique solution to the fluorescence yield
reconstruction.
Convergence of the fluorescence reconstruction algo-
rithm is achieved within 15 iterations by using a classical
iterative ART algorithm with a relaxation parameter of 0.1.
We have shown on diﬀerent mice experiments that further
iterations with this relaxation factor induce nonsignificant
variations of the ‖measures− reprojections‖ norm.
4. Measurements and Results
This section presents diﬀerent kinds of experiments con-
ducted on mice. First experiments were done to determine
the minimum fluorophore quantity required to overcome
of natural or nonspecific fluorescence. These experiments
were conducted on the laboratory setup on sacrificed mice
in which capillaries were inserted (mice no. 1 to no. 4).
Afterwards, experiments were done on the laboratory setup
to validate the feasibility of imaging tumor-bearing mice
(mice from no. 5 to no. 7). As no anaesthetic system is
installed on the laboratory setup, themice were sacrificed just
before measuring with the laboratory setup. Finally, in vivo
experiments were conducted on the industrial setup (mice
from no. 8 to no. 10).
Mice used on the laboratory setup were on a chlorophyll-
free diet before the measurements were performed, whereas
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Figure 10: Mouse no. 4, experiment on abdominal area. (a, b) XCT reconstruction only, the heterogeneous aspect of the abdomen is clearly
visible. (c, d) coregistration of the fDOT and XCT reconstructions for a mouse with 10 pmol Alexa 750 inside a capillary tube (arrow)
inserted in the abdominal area. It is possible to distinguish specific fluorescence from natural fluorescence.
mice used on the industrial setup were not. All the animals
used in this study were treated and handled according to the
animal experimentation ethical committee Cometh38 for the
laboratory setup and in strict adherence to the Swiss Law for
Animal Protection for the industrial setup.
4.1. Measurements on Dead Mice Containing a Fluorescent
Inclusion. Four experiments were conducted on mice either
on the thorax or on the abdominal area. A capillary tube—
filled with a solution of Alexa 750—was inserted either in
the lungs via the trachea or in the abdomen of sacrificed
healthy nude mice. In order to determine the concentration
of fluorophore required to overcome natural or nonspecific
fluorescence for each region of interest, we compare the
fDOT reconstruction to the reconstruction of the same
experiment with the mice imaged without the capillaries
inside.
The X-ray generator is a monoblock X-ray source,
manufactured by Gilardoni (Italy) with a CW power of
500W. The anodic voltage is tunable from 40 kV to 140 kV
allowing X-ray emission with an energy spectrum spreading
from about 5 keV to 140 keV. The flux of the radiation
emitted by the tungsten anode is controlled by the electrode
current intensity adjustable from 1mA to 7mA. In our case,
X-ray data are acquired according to a fast protocol with 400
projections at 40 kV, 6mA, and a 50 μm Tin filtering. The
Focal spot is approximately 1mm. The X-ray detector is from
Hamamatsu, Japan: C7942-CA with a 1mm aluminium
window. A preliminary Step of 4× binning (560×592 pixels2
images) reduces the size of the acquired data and is suﬃcient
for providing external shape information for fDOT. The
reconstructed volume consists of 300 × 300 × 420 voxels @
150× 150× 150μm3 (x, y, z).
fDOT data are acquired according to 40 × 12 sources
positions (12 vertical translations and 40 rotations). A
rectangular detection area is selected onto the camera images
according to the projection of the field of view and binned
to form a grid of 40× 12 detectors. Some views are removed
to avoid the artefacts induced by the mouse holder (i.e., the
views for which the optical axis intersects the mouse holder).
The total reconstructed volume is composed of 17 × 13 ×
26 voxels of 2 × 2 × 2mm3; the integration time was 3 s
per frame for fluorescence images and 400ms per frame for
diﬀusion images.
On the laboratory setup, not optimized for acquisition
times, the total X-ray acquisition takes about 5 minutes, the
DOT acquisition 20 minutes, and the fDOT acquisition 40
minutes, so about 1 hour total acquisition time per mouse.
The reconstruction time for XCT is about 10 minutes and 10
minutes for fDOT on a 2.6 Ghz PC (pentium 4).
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The coregistered fDOT and XCT images are presented
on Figures 7(a) and 7(b) (two view angles) for the lungs area
experiment onmouse no. 1. The capillary is filled with 2.5 μL
of Alexa 750 at a concentration of 2 μmol/L; that is, with a
5 pmol quantity. The results in Figure 7 highlight clearly the
position of the capillary tube visible also in XCT modality on
the left image (arrow). We localized the fluorophore in the
morphology of the animal with a tolerance of 1mm.
This experiment was repeated with a quantity of 2 pmol
in the capillary Figure 8. This was the minimal quantity
necessary to overcome the natural fluorescence in this area.
We localized the fluorophore in the morphology of the
animal with a tolerance of 1mm.
The result for the abdominal area experiment on mouse
no. 3 is presented on Figure 9. The capillary was filled with
a quantity of 5 pmol as for experiment on mouse no. 1.
The autofluorescence in the abdomen is much higher than
in the lungs, despite the chlorophyll-free diet. Therefore,
it was impossible to distinguish specific fluorescence from
autofluorescence. For this reason, we performed the same
kind of study with a fourth mouse filling the capillary with
2.5 μL of Alexa 750 at a concentration of 4 μmol/L; that is,
with a quantity of 10 pmol. The result for the abdominal
area experiment on mouse no. 4 is presented in Figure 10.
It is now possible to distinguish specific fluorescence from
natural fluorescence; the result is comparable to experiment
on mouse no. 1 on lungs.
In this first series of experiments, we determined the
minimal detectable fluorophore quantities for diﬀerent areas
of the mouse. Specifically, we found the minimum quantity
for the lungs to be 2 pmol and for the abdomen 10 pmol.
This diﬀerence is both due to the diﬀerent absorption
properties of the two types of tissue (absorbent region for
the lungs and very heterogeneous region presenting intrinsic
fluorescence for the abdomen), but also due to the diﬀerent
levels of autofluorescence present. Although we found a
sensitivity limit of 2 pmol for the lungs, we now routinely
use 5 pmol to ensure detection of capillary tubes despite
variable absorption across diﬀerent mice and depending on
the position of the tube (more diﬃcult when positioned near
the liver).
For each one of these experiments, the use of the bimodal
system leads to accurate results in terms of localisation with
a tolerance of 1mm depending of the size of the mesh (here
2mm), independent of the zone of interest. It opens the field
for further experiments of diseased mice and registration of
fluorescence sources (targeted tumors) in the anatomy of the
mouse.
4.2. Measurements on Tumor-Bearing Dead Mice. For tumor
bearing mice, we define the optical acquisition protocol with
28 × 6 sources positions (6 vertical translations and 28
rotations, that is, we suppress views of the mouse holder
at the acquisition Step) and the reconstructed volume with
29×32×48 voxels of 1×1×1mm3 to have a better resolution,
the integration time was adapted according to the position.
We used CreLox induciblep53−/−rb−/− transgenic
mice. Adenovirus encoding Cre Recombinase is adminis-
tered intratracheally, which induces lung tumor formation
in 192±36 days. We image the mice 244 days after infection:
for that 10 nmol of Angiolone (Fluoptics) marked with
AlexaFluor 700 (Invitrogen) were injected intravenously 4 h
before imaging. It has been shown that this probe targets the
αvβ3 integrin, which is overexpressed in tumors.
The fluorophore quantity is far higher than that used
for capillaries inserted into the mouse. This is calculated
based on the fact that in the animal, 1% of the injected dose
is targeted per gram of tumor, that is, 100 pmol/g tumor.
Moreover, highly diseased lungs weigh around 1 g so the
maximum quantity for any tumor is 1 g.
We show in Figure 11 the results from two mice; the
distribution obtained (small distinct tumoral sites in mouse
no. 5 and a unique large site in mouse no. 6) was confirmed
by the subsequent autopsy. As these tumours are not
visible in XCT, only qualitative localization accuracy can be
concluded. The fluorescence level has been quantified by FRI
on the lungs after excision and confirms the reconstruction
results. To verify that the fluorescence observed was specific,
a control healthy mouse, mouse no. 7, was measured and
the results are presented in Figure 12 on the same scale as
Figure 11. The detected fluorescence is far lower than for
tumour-bearing mice no. 5 and no. 6.
4.3. In Vivo Measurements on Tumor-Bearing Mice. Three in
vivo measurements were conducted on nude mice bearing
tumor xenografts using the industrial prototype. C51 tumor
cells were implanted subcutaneously close to the base of the
spine or at the thigh, ten days prior to measuring. Two of the
mice were injected with two doses of 1 nmol Prosense 680
(VisEn Medical) via the tail vein. Prosense 680 is a probe that
is activated by proteases and in particular by cathepsin, which
is overexpressed in the tumor cells used here. The first dose of
1 nmol was injected approximately 48 hours and the second
24 hours before imaging. The third mouse served as a control
and did not receive any injection of contrast agent. Before
performing the fDOT measurements, food was withdrawn
for four hours.
fDOT measurements were performed at an excitation
wavelength of 650 nm. The power applied was about 1mW
at all source positions and the integration time was 200ms
per frame.
We performed microCT measurements on a vivaCT
(SCANCO Medical) immediately after the fDOT measure-
ments. The images obtained were segmented and used to
generate the mesh for fDOT reconstruction (see (c) in
Figure 6), as described above in Section 3.1. After recon-
struction, the images obtained with the two modalities were
segmented and registered.
Figure 13 to Figure 15 show views of the registered
microCT and fDOT data obtained from the three in vivo
experiments. Postprocessing of the microCT images was
performed to visualize bone and skin. In all three cases
the tumor masses form ulcers that are readily discernable
on the microCT images. The reconstructed fluorophore
distributions are visualized as iso-surfaces, showing the
concentration at 50% of the reconstructed maxima. In
all three cases, some fluorescence is reconstructed that is
not readily attributable to the tumor tissue. Nonspecific
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Figure 11: Experiment on tumour-bearing mice, small distinct tumoral sites in the lungs of mouse no. 5 (a, b), and a unique large sites in
the lungs of mouse no. 6 (c, d).
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Figure 12: Experiment on healthy control mouse no. 7, with the same experimental protocol in Figure 11 for mice no. 5 and no. 6.
fluorescence was reconstructed in the abdomen and might
stem from fluorescent substances found in food, as those
animals were not placed in a chlorophyrle-free diet, also
due to autofluorescence or nonspecific fluorescence (i.e.,
fluorescence not targeted to tumors).
Mouse no. 8 bears one tumor (arrow) close to the
spine (Figure 13), which is clearly visible in both microCT
and fDOT modalities. Here, the maximum reconstructed
fluorophore concentration is about six times above the
maximum detected for the control case no. 10 (Figure 15).
This mouse had a second, smaller tumor close to its left
knee. An ulcer is visible in the microCT image but is not
detected by the fDOT modality. The location of the second
tumor made the measurements more challenging, as most
of the source and detector positions are at a relatively far
distance from the tumor site. Tissue at this specific location
is not optimally sampled, which might lead to a decreased
detection sensitivity at this particular location.
In mouse no. 9 (Figure 14) grew one, large tumor at
the left thigh (arrow). The tumor is clearly reconstructed by
the fDOT algorithm as a torus-like shape. Some nonspecific
fluorescence was reconstructed in the abdomen.
Figure 15 shows the distribution of fluorophore for the
control case, which is a noninjected diseased mouse (mouse
ISRN Optics 11
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Figure 13: Two views of the coregistered data obtained for mouse no. 8. The biodistribution of the protease targeting probe as obtained by
the fDOT measurement is shown in red. The threshold applied for visualization of the fluorophore distribution is 50% of the reconstructed
maximum. Skin is shown in transparent blue and bones are shown in grey.
(a) (b)
Figure 14: Two views of the coregistered data obtained on mouse no. 9. The visualization of the data is realized as described in Figure 13.
(a) (b)
Figure 15: Two views of the coregistered data obtained on mouse no. 10 (control, bearing a tumor but no protease-targeting probe was
injected). Reconstructed auto-fluorescence is shown in yellow. No fluorescence is reconstructed at the tumor site, which forms an easily
discernable ulcer close to the lower part of the spine ((b), arrow).
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no. 10). No fluorescence activity was detected in the tumor
tissue (the ulcer is visible close to the lower spine, arrow),
but some fluorescence was located in the lower abdomen.
However, the reconstructed maximum concentration is at
least a factor of 2 below the threshold applied in the two cases
discussed above.
5. Conclusion
Two systems, a laboratory setup and an industrial prototype,
dedicated to the multimodal optical and X-ray measure-
ments, have been developed. Experiments have been suc-
cessfully conducted on sacrificed mice with a capillary tube
containing Alexa750, inserted either in the trachea or the
abdomen. We have thus determined the limit of sensitivity
of the laboratory system to detect fluorescence signal over
natural or nonspecific fluorescence. For lung area, this limit
is 5 pmol; for the abdomen it is 10 pmol. The fluorophore
localization is in accordance with the X-ray reconstruction.
Some experiments on mice bearing tumors showed that
the reconstructed fluorescence in the case of mice without
tumors is far lower than the quantity reconstructed for
mice bearing tumors. In these reconstructions, artefacts and
nonspecific fluorescence are reconstructed. Artefacts can be
due to areas that are slightly thicker at certain angles of view
or to themouse holder itself. The optical acquisition protocol
has been adapted to suppress these views. Measurements
with the industrial prototype confirm and extend that the
proposed method can be used for in vivo imaging of tumors
in mice. Increased protease activity was visualized in the
tissue of subcutaneous tumor xenografts. Autofluorescence
seems not to be an issue in this kind of experiments even
if the mice are not on a chlorophyll-free diet prior to
measuring. The systems were successfully applied to diﬀerent
regions of the mouse anatomy that is, trachea, abdomen,
pelvis, and for deeply sited tumors/fluorophore inclusions as
well as for subcutaneous tumors.
In this paper, the optical reconstructions were performed
with no prior knowledge on the position of the fluorophore.
The use of XCT as prior knowledge oﬀers others advantages
[26, 27]. It allows, for example, to speed up the computation
by introducing some spatial constraints and prior knowledge
[28]. Future work will address the use of a priori as a
regularization factor in the optical reconstruction scheme
and particularly in a better estimation of the “heterogeneities
map” increasing the accuracy of the reconstructions of
the parameters extracted from optical measurements more
accurate. Furthermore, knowing the position of the organs
from the CT reconstruction, and constraining the optical
reconstruction algorithm, the optical reconstruction of the
fluorescence would be also more accurate [29].
The precise coregistering of fDOT with X-ray μCT
data/images allows evaluation of molecular information
from marked labelled tissue within its anatomical context.
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